GLP-1 drug comparisons: stomach side effects in trials
Each page puts two drugs side by side for nausea, vomiting, diarrhoea, constipation: how often people in each drug’s own trial arms reported them, in plain words first and then with 95% intervals and trial counts. Pooled from results posted to ClinicalTrials.gov, as held in our corpus on 9 October 2026. These are not head-to-head trials and not medical advice — talk to your doctor.
Semaglutide vs tirzepatide
Semaglutide (injectable): 4 of 4 effects with a published rate · Tirzepatide: 4 of 4
Oral vs injectable semaglutide
Semaglutide (oral): 4 of 4 effects with a published rate · Semaglutide (injectable): 4 of 4
Semaglutide vs liraglutide
Semaglutide (injectable): 4 of 4 effects with a published rate · Liraglutide: 4 of 4
Semaglutide vs dulaglutide
Semaglutide (injectable): 4 of 4 effects with a published rate · Dulaglutide: 4 of 4
Tirzepatide vs liraglutide
Tirzepatide: 4 of 4 effects with a published rate · Liraglutide: 4 of 4
Tirzepatide vs dulaglutide
Tirzepatide: 4 of 4 effects with a published rate · Dulaglutide: 4 of 4
Oral semaglutide vs tirzepatide
Semaglutide (oral): 4 of 4 effects with a published rate · Tirzepatide: 4 of 4
Liraglutide vs dulaglutide
Liraglutide: 4 of 4 effects with a published rate · Dulaglutide: 4 of 4
Semaglutide vs exenatide
Semaglutide (injectable): 4 of 4 effects with a published rate · Exenatide: 4 of 4
All figures come from the free sample of our GLP-1 tolerability benchmark, which covers every effect we track per drug in our corpus, with the trial arms behind each number; an effect with fewer than 3 trials is marked “insufficient data”, never filled.